Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback